An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series - 13/01/13
, Clare E. Foss, MD b, Stefanie A. Hirano, MD b, Tina D. Cunningham, PhD c, David M. Pariser, MD a, bAbstract |
Background |
Current treatments for chronic lichen planus (LP) are often ineffective and may have significant adverse side effects. An alternative safe and effective treatment for recalcitrant LP is needed.
Objectives |
We sought to study the safety and efficacy of apremilast in the treatment of moderate to severe LP.
Methods |
Ten patients with biopsy-proven LP received 20 mg of apremilast orally twice daily for 12 weeks with 4 weeks of treatment-free follow-up. The primary efficacy end point was the proportion of patients achieving a 2-grade or more improvement in the Physician Global Assessment (PGA) after 12 weeks of treatment.
Results |
Three (30%) of the 10 patients achieved a 2-grade or more improvement in the PGA after 12 weeks of treatment; however, all patients demonstrated statistically significant clinical improvement with respect to secondary parameters between baseline and the end of treatment.
Limitations |
It may be difficult to generalize the results of this study to a larger patient population with LP because of our small sample size and lack of a control group. In addition, a longer treatment period or higher dose may have been needed for therapeutic efficacy. The safety and efficacy of long-term apremilast therapy is currently unknown.
Conclusion |
Apremilast may be efficacious in the treatment of LP, but double-blinded, controlled trials are necessary to thoroughly evaluate its safety and efficacy.
Le texte complet de cet article est disponible en PDF.Key words : apremilast, interferon-γ, interleukin, leukotriene B4, lichen planus, treatment, tumor necrosis factor-α
Abbreviations used : AE, ANA, DLQI, IL, LP, PGA, PGAMD, SGA, SVAS, TALSS
Plan
| Supported by an unrestricted grant from Celgene Corp. |
|
| Disclosure: Dr Pariser is an investigator for Abbott, Amgen, Basilea, Celgene, Dow, Eli Lilly, Galderma, Graceway, Intendis, Johnson and Johnson Consumer Products, Leo Pharma, Novo Nordisk, Ortho Dermatologics, Peplin, Pfizer, Photocure, and Stiefel. He is also on the advisory board or is a consultant for Abbott, Galderma, Medicis, Mela Sciences, Ortho Dermatologics, Pfizer, and Stiefel. Drs Paul, Foss, Hirano, and Cunningham have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 68 - N° 2
P. 255-261 - février 2013 Retour au numéro
Article précédent
- Acitretin for the treatment of cutaneous T-cell lymphoma
- Justin Cheeley, Rachel E. Sahn, Laura K. DeLong, Sareeta R. Parker
- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis
- Katrina Abuabara, Joy Wan, Andrea B. Troxel, Daniel B. Shin, Abby S. Van Voorhees, Bruce F. Bebo, Gerald G. Krueger, Kristina Callis Duffin, Joel M. Gelfand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?